Javascript must be enabled to continue!
Abstract 1195: Erk activity promotes Notch-dependent HES1 expression in pancreatic cancer cells
View through CrossRef
Abstract
The oncogene Ras is well-recognized for its involvement in tumorigenesis in part through activation of downstream pathways including the PI3K/Akt and Mek/Erk pathways. Recent studies have suggested that the ability of Ras to transform cells also depends on cooperation with the Notch signalling pathway. However, the molecular and cellular mechanisms involved in this cooperation remain largely unknown. The aim of this study was to evaluate whether specific activation of the Ras/Raf/Mek/Erk pathway impacts Notch-dependent signalling. METHODS. Experiments were done using the pancreatic cancer cells MIA PaCa-2 and BxPC-3. Both cell lines express endogenous levels of the activated Notch1 (NIC). To inhibit Mek/Erk activity, cells were treated with the Mek inhibitor U0126 (10uM). Activation of the Mek/Erk pathway was achieved by treatment with phorbol 12-myristate 13-acetate (PMA, 100nM). The hes1-luciferase reporter gene was used to evaluate Notch-dependent transcriptional activity. The gamma-secretase inhibitor DAPT (25µM) was used to inhibit Notch activation. RESULTS. 1- Treatment of pancreatic cancer cells with U0126 reduced the activity of the hes1-luciferase reporter gene to the same extent than treatment with the gamma-secretase inhibitor DAPT. 2- Combined treatment (U0126 + DAPT) did not result in an additive inhibition of hes1-luciferase activity suggesting a Notch-dependent impact of the Mek inhibitor on hes1 transcription. 3- Increased HES1 mRNA expression levels were observed following treatment with PMA, an effect prevented by addition of U0126. 4- Massive activation of the Notch receptors by treatment with EGTA promoted HES1 protein expression. 5- Interestingly, strong stimulation of Erk activity by PMA promoted the EGTA-induced HES1 protein expression. 6- Conversely, inhibition of Erk activity completely prevented both the EGTA-induced and EGTA+PMA-induced HES1 protein expression. CONCLUSION. Taken together, our results suggest that Erk activity promotes Notch-dependent transcriptional activity and consequently promotes the expression of Notch target genes such as HES1.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1195. doi:1538-7445.AM2012-1195
American Association for Cancer Research (AACR)
Title: Abstract 1195: Erk activity promotes Notch-dependent HES1 expression in pancreatic cancer cells
Description:
Abstract
The oncogene Ras is well-recognized for its involvement in tumorigenesis in part through activation of downstream pathways including the PI3K/Akt and Mek/Erk pathways.
Recent studies have suggested that the ability of Ras to transform cells also depends on cooperation with the Notch signalling pathway.
However, the molecular and cellular mechanisms involved in this cooperation remain largely unknown.
The aim of this study was to evaluate whether specific activation of the Ras/Raf/Mek/Erk pathway impacts Notch-dependent signalling.
METHODS.
Experiments were done using the pancreatic cancer cells MIA PaCa-2 and BxPC-3.
Both cell lines express endogenous levels of the activated Notch1 (NIC).
To inhibit Mek/Erk activity, cells were treated with the Mek inhibitor U0126 (10uM).
Activation of the Mek/Erk pathway was achieved by treatment with phorbol 12-myristate 13-acetate (PMA, 100nM).
The hes1-luciferase reporter gene was used to evaluate Notch-dependent transcriptional activity.
The gamma-secretase inhibitor DAPT (25µM) was used to inhibit Notch activation.
RESULTS.
1- Treatment of pancreatic cancer cells with U0126 reduced the activity of the hes1-luciferase reporter gene to the same extent than treatment with the gamma-secretase inhibitor DAPT.
2- Combined treatment (U0126 + DAPT) did not result in an additive inhibition of hes1-luciferase activity suggesting a Notch-dependent impact of the Mek inhibitor on hes1 transcription.
3- Increased HES1 mRNA expression levels were observed following treatment with PMA, an effect prevented by addition of U0126.
4- Massive activation of the Notch receptors by treatment with EGTA promoted HES1 protein expression.
5- Interestingly, strong stimulation of Erk activity by PMA promoted the EGTA-induced HES1 protein expression.
6- Conversely, inhibition of Erk activity completely prevented both the EGTA-induced and EGTA+PMA-induced HES1 protein expression.
CONCLUSION.
Taken together, our results suggest that Erk activity promotes Notch-dependent transcriptional activity and consequently promotes the expression of Notch target genes such as HES1.
Citation Format: {Authors}.
{Abstract title} [abstract].
In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL.
Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1195.
doi:1538-7445.
AM2012-1195.
Related Results
Abstract 1534: Hes1 regulates hypoxia induced chemoresistance of myeloma cells
Abstract 1534: Hes1 regulates hypoxia induced chemoresistance of myeloma cells
Abstract
Bone marrow (BM) microenvironment plays a critical role in response of tumor cells to chemotherapeutic drugs. Hypoxia has been shown to contribute to pathog...
Abstract 1566: Notch-1 regulation of the PTEN - mTOR axis in prostate
Abstract 1566: Notch-1 regulation of the PTEN - mTOR axis in prostate
Abstract
Prostate cancer affects one in three men over the age of 60. Loss of expression or function of PTEN is the most commonly observed molecular defect in human ...
HES1 promotes aerobic glycolysis and cancer progression of colorectal cancer via IGF2BP2-mediated GLUT1 m6A modification
HES1 promotes aerobic glycolysis and cancer progression of colorectal cancer via IGF2BP2-mediated GLUT1 m6A modification
Abstract
HES1 plays a critical role in promoting tumor progression, but the underlying mechanisms are only partially understood. Here, we found that HES1 expression was sig...
Role of Stromal Cell-Mediated Notch Signaling in AML Resistance to Chemotherapy
Role of Stromal Cell-Mediated Notch Signaling in AML Resistance to Chemotherapy
Abstract
Introduction: Our group has recently shown that bone marrow-mesenchymal stromal cell (BM-MSCs)-mediated Notch signaling may control survival and chemoresist...
Abstract 1709: STRAP mediates the stemness of human colorectal cancer cells by epigenetic regulation of Notch pathway
Abstract 1709: STRAP mediates the stemness of human colorectal cancer cells by epigenetic regulation of Notch pathway
Abstract
Human colon cancer-initiating cells (CCICs) are responsible for the unrestrained cell proliferation and chemoresistance of colorectal tumors. Notch signalin...
Abstract 1133: Prevalence of activated NOTCH receptor in solid tumors and chronic lymphocytic leukemia
Abstract 1133: Prevalence of activated NOTCH receptor in solid tumors and chronic lymphocytic leukemia
Abstract
Recent reports identified high expression of Notch 1 receptor in various tumors including adenoid cystic carcinomas (ACC). Notch 1 receptor is activated by ...
Abstract 1823: Novel regulation of Jagged1 by ErbB2 in breast cancer: implications for anti-ErbB2 therapy
Abstract 1823: Novel regulation of Jagged1 by ErbB2 in breast cancer: implications for anti-ErbB2 therapy
Abstract
We have demonstrated that Notch1 is required for trastuzumab resistance in ErbB2 positive breast cancer. This indicates that ErbB2 suppresses Notch1 in brea...
Abstract IA-08: Clinical advances in pancreas adenocarcinoma
Abstract IA-08: Clinical advances in pancreas adenocarcinoma
Abstract
Pancreatic adenocarcinoma (PDAC) remains one of the most lethal cancers today and is expected to be the second cause of cancer death in the coming decade. M...

